Credit: Burgess et al., 2023, PLOS Global Public Health, CC-BY 4.0
A) Total and B) breakthrough varicella incidence over time, by vaccination strategy. Panel A: Total varicella incidence, including natural and breakthrough cases, over 50 years after the start of universal childhood varicella vaccination. Panel B: Breakthrough varicella incidence over 50 years. In both panels, varicella incidence with strategies E and F were the same as for strategies C and D, respectively. Strategy A: V-MSD (12 months) + V-MSD (15 months); Strategy B: V-GSK (12 months) + V-GSK (15 months); Strategy C: V-MSD (15 months) + V-MSD (48 months); Strategy D: V-GSK (15 months) + V-GSK (48 months); Strategy E: V-MSD (15 months) + MMRV-MSD (48 months); Strategy F: V-GSK (15 months) + MMRV-GSK (48 months).